HIGHLIGHTS FROM THE ESMO IMMUNO ONCOLOGY CONGRESS
Studies shed new light on the role of the gut microbiome in immunotherapy toxicity
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
Immunotherapy added to radiotherapy does not improve outcomes in early-stage NSCLC
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
Are we close to personalise immunotherapy?
According to the 2024 ESMO Immuno-Oncology Awardee, Ton Schumacher, tackling the T-cell receptor challenge with vast datasets and cutting-edge high-throughput methods may pave the way for advances in the field
HIGHLIGHTS FROM THE ESMO ASIA CONGRESS
Short durvalumab infusions appear to be safe for the first-line treatment of advanced biliary tract cancer
Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients
Two oral immune checkpoint inhibitors show preliminary efficacy and manageable safety in early trials
Promising results support the further development of new small-molecule PD-L1 inhibitors with favourable benefit–risk profiles and improved ease of use compared with antibodies
Studies show two promising new immune-related targets in cancer
Agents targeting B7-H3 and CEACAM6 pass their initial clinical tests, according to results from first-in-human trials
Three new Pan-Asian-adapted guidelines at ESMO Asia Congress
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
Targeting claudins in pancreatic adenocarcinoma is promising, early-phase findings suggest
Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate
Immunotherapy combinations consolidate their place in the first-line treatment of unresectable hepatocellular carcinoma
Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function
COLUMNS
Redispensing cancer medicines means caring for the environment
Some initiatives show that collection and distribution of unused medicines can help tackle drug waste, with a potential impact on emissions associated to oncology therapies
The expanding toolbox for immuno-oncology
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
Off-label use of cancer medicines: an option not without challenges
Together with an off-trial use and off-track access to oncology therapies, a consolidated trend is reported in clinical practice despite the uncertainties on efficacy and safety
OPINIONS
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Christian Blank
Preventing the rise in obesity-related cancers in Asia
Elick Narayan
Translating cancer genome insights into practical clinical tools
Elli Papaemmanuil
Innovation is leading to a comprehensive ‘map’ of tumours
Joakim Lundeberg
How to bridge the gap between palliative care and oncology?
Rita Canario
ESMO Immuno-Oncology 2024 Congress: an event to explore challenges and emerging trends in the field
All videosOPINIONS
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Christian Blank
Preventing the rise in obesity-related cancers in Asia
Elick Narayan
Translating cancer genome insights into practical clinical tools
Elli Papaemmanuil
Innovation is leading to a comprehensive ‘map’ of tumours
Joakim Lundeberg
How to bridge the gap between palliative care and oncology?
Rita Canario